Therapeutic Proteins

  • Dimiter S. DimitrovEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 899)


Protein-based therapeutics are highly successful in clinic and currently enjoy unprecedented recognition of their potential. More than 100 genuine and similar number of modified therapeutic proteins are approved for clinical use in the European Union and the USA with 2010 sales of US$108 bln; monoclonal antibodies (mAbs) accounted for almost half (48%) of the sales. Based on their pharmacological activity, they can be divided into five groups: (a) replacing a protein that is deficient or abnormal; (b) augmenting an existing pathway; (c) providing a novel function or activity; (d) interfering with a molecule or organism; and (e) delivering other compounds or proteins, such as a radionuclide, cytotoxic drug, or effector proteins. Therapeutic proteins can also be grouped based on their molecular types that include antibody-based drugs, Fc fusion proteins, anticoagulants, blood factors, bone morphogenetic proteins, engineered protein scaffolds, enzymes, growth factors, hormones, interferons, interleukins, and thrombolytics. They can also be classified based on their molecular mechanism of activity as (a) binding non-covalently to target, e.g., mAbs; (b) affecting covalent bonds, e.g., enzymes; and (c) exerting activity without specific interactions, e.g., serum albumin. Most protein therapeutics currently on the market are recombinant and hundreds of them are in clinical trials for therapy of cancers, immune disorders, infections, and other diseases. New engineered proteins, including bispecific mAbs and multispecific fusion proteins, mAbs conjugated with small molecule drugs, and proteins with optimized pharmacokinetics, are currently under development. However, in the last several decades, there are no conceptually new methodological developments comparable, e.g., to genetic engineering leading to the development of recombinant therapeutic proteins. It appears that a paradigm change in methodologies and understanding of mechanisms is needed to overcome major challenges, including resistance to therapy, access to targets, complexity of biological systems, and individual variations.

Key words

Therapeutics Proteins Antibodies Vaccines Cancer Immune diseases Immunogenicity Safety Efficacy 



I would like to thank members of the group Protein Interactions, especially W. Chen, X. Xiao, Z. Zhu, Y. Feng, E. Streaker, and J. Owens for discussions, experiments and help, and the Editor V. Voynov for helpful suggestions which improved this article. This study was supported by the NIH NCI CCR intramural program, the NIH intramural AIDS program (IATAP), and the NIAID intramural biodefense program.


  1. 1.
    Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6:343–357PubMedCrossRefGoogle Scholar
  2. 2.
    Schrama D, Reisfeld RA, Becker JC (2006) Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5:147–159PubMedCrossRefGoogle Scholar
  3. 3.
    Waldmann TA (2003) Immunotherapy: past, present and future. Nat Med 9:269–277PubMedCrossRefGoogle Scholar
  4. 4.
    Casadevall A, Dadachova E, Pirofski LA (2004) Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2:695–703PubMedCrossRefGoogle Scholar
  5. 5.
    Carter PJ (2011) Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res 317:1261–1269PubMedCrossRefGoogle Scholar
  6. 6.
    Dimitrov DS (2010) Therapeutic antibodies, vaccines and antibodyomes. MAbs 2:347–356PubMedCrossRefGoogle Scholar
  7. 7.
    Walsh G (2010) Biopharmaceutical benchmarks 2010. Nat Biotechnol 28:917–924PubMedCrossRefGoogle Scholar
  8. 8.
    Leader B, Baca QJ, Golan DE (2008) Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 7:21–39PubMedCrossRefGoogle Scholar
  9. 9.
    Dimitrov DS, Marks JD (2009) Therapeutic antibodies: current state and future trends—is a paradigm change coming soon? Methods Mol Biol 525:1–27PubMedCrossRefGoogle Scholar
  10. 10.
    Ashkenazi A (2008) Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 7:1001–1012PubMedCrossRefGoogle Scholar
  11. 11.
    Beck A, Reichert JM (2011) Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs 3(5):415–416PubMedCrossRefGoogle Scholar
  12. 12.
    Reichert JM (2011) Antibody-based therapeutics to watch in 2011. MAbs 3:76–99PubMedCrossRefGoogle Scholar
  13. 13.
    Reichert JM (2010) Metrics for antibody therapeutics development. MAbs 2:695–700PubMedCrossRefGoogle Scholar
  14. 14.
    Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497PubMedCrossRefGoogle Scholar
  15. 15.
    Goeddel DV, Kleid DG, Bolivar F, Heyneker HL, Yansura DG, Crea R, Hirose T, Kraszewski A, Itakura K, Riggs AD (1979) Expression in Escherichia coli of chemically synthesized genes for human insulin. Proc Natl Acad Sci USA 76:106–110PubMedCrossRefGoogle Scholar
  16. 16.
    Feng Y, Dimitrov DS (2008) Monoclonal antibodies against components of the IGF system for cancer treatment. Curr Opin Drug Discov Devel 11:178–185PubMedGoogle Scholar
  17. 17.
    Wu H, Pfarr DS, Tang Y, An LL, Patel NK, Watkins JD, Huse WD, Kiener PA, Young JF (2005) Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol 350:126–144PubMedCrossRefGoogle Scholar
  18. 18.
    Skerra A (2007) Alternative non-antibody scaffolds for molecular recognition. Curr Opin Biotechnol 18:295–304PubMedCrossRefGoogle Scholar
  19. 19.
    Chen W, Dimitrov DS (2009) Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors. Curr Opin HIV AIDS 4:112–117PubMedCrossRefGoogle Scholar
  20. 20.
    Chen W, Zhu Z, Feng Y, Xiao X, Dimitrov DS (2008) Construction of a large phage-displayed human antibody domain library with a scaffold based on a newly identified highly soluble, stable heavy chain variable domain. J Mol Biol 382:779–789PubMedCrossRefGoogle Scholar
  21. 21.
    Chen W, Zhu Z, Feng Y, Dimitrov DS (2008) Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc Natl Acad Sci USA 105:17121–17126PubMedCrossRefGoogle Scholar
  22. 22.
    Chen W, Xiao X, Wang Y, Zhu Z, Dimitrov DS (2010) Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates. Antiviral Res 88:107–115PubMedCrossRefGoogle Scholar
  23. 23.
    Dimitrov DS (2009) Engineered CH2 domains (nanoantibodies). MAbs 1:26–28PubMedCrossRefGoogle Scholar
  24. 24.
    Xiao X, Feng Y, Vu BK, Ishima R, Dimitrov DS (2009) A large library based on a novel (CH2) scaffold: identification of HIV-1 inhibitors. Biochem Biophys Res Commun 387:387–392PubMedCrossRefGoogle Scholar
  25. 25.
    Gong R, Vu BK, Feng Y, Prieto DA, Dyba MA, Walsh JD, Prabakaran P, Veenstra TD, Tarasov SG, Ishima R, Dimitrov DS (2009) Engineered human antibody constant domains with increased stability. J Biol Chem 284:14203–14210PubMedCrossRefGoogle Scholar
  26. 26.
    Gong R, Wang Y, Feng Y, Zhao Q, Dimitrov DS (2011) Shortened engineered human antibody CH2 domains: increased stability and binding to the human neonatal receptor. J Biol Chem 286(3):27288–27293PubMedCrossRefGoogle Scholar
  27. 27.
    Jiang XR, Song A, Bergelson S, Arroll T, Parekh B, May K, Chung S, Strouse R, Mire-Sluis A, Schenerman M (2011) Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov 10:101–111PubMedCrossRefGoogle Scholar
  28. 28.
    Descotes J, Gouraud A (2008) Clinical immunotoxicity of therapeutic proteins. Expert Opin Drug Metab Toxicol 4:1537–1549PubMedCrossRefGoogle Scholar
  29. 29.
    Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355:1018–1028PubMedCrossRefGoogle Scholar
  30. 30.
    Ewer SM, Ewer MS (2008) Cardiotoxicity profile of trastuzumab. Drug Saf 31:459–467PubMedCrossRefGoogle Scholar
  31. 31.
    Chung CH (2008) Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 13:725–732PubMedCrossRefGoogle Scholar
  32. 32.
    Winter MC, Hancock BW (2009) Ten years of rituximab in NHL. Expert Opin Drug Saf 8:223–235PubMedCrossRefGoogle Scholar
  33. 33.
    Pendley C, Schantz A, Wagner C (2003) Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther 5:172–179PubMedGoogle Scholar
  34. 34.
    Schellekens H (2008) How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnol Annu Rev 14:191–202PubMedCrossRefGoogle Scholar
  35. 35.
    Onda M (2009) Reducing the immunogenicity of protein therapeutics. Curr Drug Targets 10:131–139PubMedCrossRefGoogle Scholar
  36. 36.
    Baker MP, Jones TD (2007) Identification and removal of immunogenicity in therapeutic proteins. Curr Opin Drug Discov Devel 10:219–227PubMedGoogle Scholar
  37. 37.
    Stas P, Lasters I (2009) Strategies for preclinical immunogenicity assessment of protein therapeutics. IDrugs 12:169–173PubMedGoogle Scholar
  38. 38.
    De Groot AS, McMurry J, Moise L (2008) Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. Curr Opin Pharmacol 8:620–626PubMedCrossRefGoogle Scholar
  39. 39.
    Emi AN, de Carvalho JF, Artur Almeida SC, Bonfa E (2010) Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol 38(2–3):82–89Google Scholar
  40. 40.
    Hangartner L, Zinkernagel RM, Hengartner H (2006) Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 6:231–243PubMedCrossRefGoogle Scholar
  41. 41.
    Dixit R, Coats S (2009) Preclinical efficacy and safety models for mAbs: the challenge of developing effective model systems. IDrugs 12:103–108PubMedGoogle Scholar
  42. 42.
    Castillo J, Winer E, Quesenberry P (2008) Newer monoclonal antibodies for hematological malignancies. Exp Hematol 36:755–768PubMedCrossRefGoogle Scholar
  43. 43.
    Mariani G, Fasolo A, De BE, Gianni L (2009) Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nat Clin Pract Oncol 6:93–104PubMedCrossRefGoogle Scholar
  44. 44.
    Bedard PL, Piccart-Gebhart MJ (2008) Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer. Clin Breast Cancer 8(Suppl 4):S157–S165PubMedCrossRefGoogle Scholar
  45. 45.
    Hall PS, Cameron DA (2009) Current perspective—trastuzumab. Eur J Cancer 45:12–18PubMedCrossRefGoogle Scholar
  46. 46.
    Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112:533–543PubMedCrossRefGoogle Scholar
  47. 47.
    Norden AD, Drappatz J, Wen PY (2008) Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 7:1152–1160PubMedCrossRefGoogle Scholar
  48. 48.
    Sachdev JC, Jahanzeb M (2008) Evolution of bevacizumab-based therapy in the management of breast cancer. Clin Breast Cancer 8:402–410PubMedCrossRefGoogle Scholar
  49. 49.
    Patel DK (2008) Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. Pharmacotherapy 28:31S–41SPubMedCrossRefGoogle Scholar
  50. 50.
    Tassev DV, Cheung NK (2009) Monoclonal antibody therapies for solid tumors. Expert Opin Biol Ther 9:341–353PubMedCrossRefGoogle Scholar
  51. 51.
    Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov I (2009) Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin Ther Targets 13:339–362PubMedCrossRefGoogle Scholar
  52. 52.
    Presta LG (2008) Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 20:460–470PubMedCrossRefGoogle Scholar
  53. 53.
    Jefferis R (2009) Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 8:226–234PubMedCrossRefGoogle Scholar
  54. 54.
    Labrijn AF, Aalberse RC, Schuurman J (2008) When binding is enough: nonactivating antibody formats. Curr Opin Immunol 20:479–485PubMedCrossRefGoogle Scholar
  55. 55.
    Kiewe P, Thiel E (2008) Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opin Investig Drugs 17:1553–1558PubMedCrossRefGoogle Scholar
  56. 56.
    Weber J (2009) Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 58:823–830PubMedCrossRefGoogle Scholar
  57. 57.
    Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jungbluth AA, Segal NH, Rasalan TS, Manukian G, Xu Y, Roman RA, Terzulli SL, Heywood M, Pogoriler E, Ritter G, Old LJ, Allison JP, Wolchok JD (2008) CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci USA 105:20410–20415PubMedCrossRefGoogle Scholar
  58. 58.
    Bellail AC, Qi L, Mulligan P, Chhabra V, Hao C (2009) TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials 4:34–41PubMedCrossRefGoogle Scholar
  59. 59.
    Feng Y, Xiao X, Zhu Z, Dimitrov DS (2010) Identification and characterization of a novel agonistic anti-DR4 human monoclonal antibody. MAbs 2:565–570PubMedCrossRefGoogle Scholar
  60. 60.
    Zhang MY, Shu Y, Phogat S, Xiao X, Cham F, Bouma P, Choudhary A, Feng YR, Sanz I, Rybak S, Broder CC, Quinnan GV, Evans T, Dimitrov DS (2003) Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. J Immunol Methods 283:17–25PubMedCrossRefGoogle Scholar
  61. 61.
    Choudhry V, Zhang MY, Sidorov IA, Louis JM, Harris I, Dimitrov AS, Bouma P, Cham F, Choudhary A, Rybak SM, Fouts T, Montefiori DC, Broder CC, Quinnan GV Jr, Dimitrov DS (2007) Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. Virology 363:79–90PubMedCrossRefGoogle Scholar
  62. 62.
    Zhang MY, Dimitrov DS (2007) Novel approaches for identification of broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies and improvement of their potency. Curr Pharm Des 13:203–212PubMedCrossRefGoogle Scholar
  63. 63.
    Liu H, Gaza-Bulseco G, Faldu D, Chumsae C, Sun J (2008) Heterogeneity of monoclonal antibodies. J Pharm Sci 97:2426–2447PubMedCrossRefGoogle Scholar
  64. 64.
    Birch JR, Racher AJ (2006) Antibody production. Adv Drug Deliv Rev 58:671–685PubMedCrossRefGoogle Scholar
  65. 65.
    Zhou JX, Tressel T, Yang X, Seewoester T (2008) Implementation of advanced technologies in commercial monoclonal antibody production. Biotechnol J 3:1185–1200PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Protein Interactions Group, Frederick National Laboratory for Cancer ResearchNational Cancer Institute, National Institutes of HealthFrederickUSA

Personalised recommendations